Jump to content

FDA OKs Topical Gel to Take Red Out of Rosacea - (Mirvaso)


Recommended Posts

  • Root Admin

Galderma now shipping new topical rosacea treatment - Mirvaso Gel


Galderma headquarters in Fort Worth.

Photo courtesy of Galderma


FDA OKs Topical Gel to Take Red Out of Rosacea


FDA OKs First Topical Agent for Facial Erythema of Rosacea Medscape

FDA Approves 1st Topical Gel to Ease Redness of Rosacea - US News and World Report

Mirvaso Gel for Rosacea Now Available - MPR


Mirvaso Savings Card Coupon


MIRVASO (brimonidine) 0.33% Topical Gel

Mirvaso® (brimonidine) topical gel, 0.33% is an alpha-2 adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin-burning sensation and contact dermatitis.

Warnings/Precautions: Mirvaso gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögrens syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso gel by children have been reported.

Keep Mirvaso gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.



For more information read the reports of actual users of Mirvaso:

Go to this page (scroll down to subheading 'Anecdotal Reports'}

Link to comment
Share on other sites

  • 4 weeks later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use